[
  {
    "ts": null,
    "headline": "Tracking Baker Brothers Portfolio - Q3 2024 Update",
    "summary": "Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other small-cap firms. Read more here.",
    "url": "https://finnhub.io/api/news?id=bb826d60bff05043f09f6c45637ba7ccbfac2459b59b40e324a670af6dc2f559",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733960303,
      "headline": "Tracking Baker Brothers Portfolio - Q3 2024 Update",
      "id": 131923910,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160060870/image_1160060870.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other small-cap firms. Read more here.",
      "url": "https://finnhub.io/api/news?id=bb826d60bff05043f09f6c45637ba7ccbfac2459b59b40e324a670af6dc2f559"
    }
  },
  {
    "ts": null,
    "headline": "ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma",
    "summary": "The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.",
    "url": "https://finnhub.io/api/news?id=add124fd36bfca472632a583285fe1a5df7581bf9089bfd5bcc4307082f68725",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733958380,
      "headline": "ASH 2024: inMIND study results position Monjuvi as a promising therapy for R/R follicular lymphoma",
      "id": 131929142,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/GettyImages-1866586143.jpg",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.",
      "url": "https://finnhub.io/api/news?id=add124fd36bfca472632a583285fe1a5df7581bf9089bfd5bcc4307082f68725"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp. stock rises Wednesday, still underperforms market",
    "summary": "Incyte Corp. stock rises Wednesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=374b6a20d659090fe5fe119f827ec09110acc6d407ecfa8a8b0a171f73b4e17f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733937300,
      "headline": "Incyte Corp. stock rises Wednesday, still underperforms market",
      "id": 131953940,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock rises Wednesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=374b6a20d659090fe5fe119f827ec09110acc6d407ecfa8a8b0a171f73b4e17f"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More",
    "summary": "It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.",
    "url": "https://finnhub.io/api/news?id=91e4c2858f97b3948d4a425619ba49945e3915cda783779805c5cd654992d6db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733928900,
      "headline": "Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More",
      "id": 131925975,
      "image": "https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight.",
      "url": "https://finnhub.io/api/news?id=91e4c2858f97b3948d4a425619ba49945e3915cda783779805c5cd654992d6db"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Late-Breaking Tafasitamab (Monjuvi) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma",
    "summary": "WILMINGTON, Del. - Incyte today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab , a humanized Fc-modified cytolytic CD19 targeting monoclonal...",
    "url": "https://finnhub.io/api/news?id=237175447da3f64d7d17cae885249b61c94b8394a3b74aba06da413f0f9ce4f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733916869,
      "headline": "Incyte Late-Breaking Tafasitamab (Monjuvi) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma",
      "id": 131920725,
      "image": "",
      "related": "INCY",
      "source": "Finnhub",
      "summary": "WILMINGTON, Del. - Incyte today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab , a humanized Fc-modified cytolytic CD19 targeting monoclonal...",
      "url": "https://finnhub.io/api/news?id=237175447da3f64d7d17cae885249b61c94b8394a3b74aba06da413f0f9ce4f2"
    }
  }
]